CD274 and non-small cell lung carcinoma: An ongoing phase III study (SKYSCRAPER-01) in advanced NSCLC patients with PD-L1 TPS ≥ 50% failed in meeting its co-primary endpoint of PFS and demonstrated a numerical but not statistically significant benefit in OS of tiragolumab + atezolizumab versus atezolizumab alone based on the disclosure of a second interim analysis [141].